Citations

Clear

6273 citation(s) found for "To, Andrew".

A rare sequence variant in intron 1 of THAP1 is associated with primary dystonia
Vemula, Satya R. , Xiao, Jianfeng , Zhao, Yu , Bastian, Robert W., Racette, Brad A. , Paniello, Randal C., Uitti, Ryan J. , Gerpen, Jay A. van, Hedera, Peter , Truong, Daniel , Blitzer, Andrew , Rudzińska, Monika , Momčilović, Dragana, Frei, Karen , Pfeiffer, Ronald F. , LeDoux, Mark S. , Van Gerpen, Jay A, Perlmutter, Joel S. , Wszołek, Zbigniew K. , Jinnah, H. A. , Rudzinska-Bar, Monika

Mayo Clinic

Molecular Genetics & Genomic Medicine | February 12, 2014 | Volume: 2 | Issue: 3 | Pages: 261-272

10.1002/mgg3.67 | PMID 24936516 Get It

AbstractAlthough coding variants in THAP1 have been causally associated with primary dystonia, the contribution of noncoding variants remains uncertain. Herein, we examine a previously identified Intron 1 variant (c.71+9C>A, rs200209986). Among 1672 subjects with mainly adult‐onset primary dystonia, 12 harbored the variant in contrast to 1/1574 controls (P < 0.01). Dystonia classification included cervical dystonia (N = 3), laryngeal dystonia (adductor subtype, N = 3), jaw‐opening oromandibular dystonia (N = 1), blepharospasm (N = 2), and unclassified (N = 3). Age of dystonia onset ranged from 25 to 69 years (mean = 54 years). In comparison to controls with no identified THAP1 sequence variants, the c.71+9C>A variant was associated with an elevated ratio of Isoform 1 (NM_018105) to Isoform 2 (NM_199003) in leukocytes. In silico and minigene analyses indicated that c.71+9C>A alters THAP1 splicing. Lymphoblastoid cells harboring the c.71+9C>A variant showed extensive apoptosis with relatively fewer cells in the G2 phase of the cell cycle. Differentially expressed genes from lymphoblastoid cells revealed that the c.71+9C>A variant exerts effects on DNA synthesis, cell growth and proliferation, cell survival, and cytotoxicity. In aggregate, these data indicate that THAP1 c.71+9C>A is a risk factor for adult‐onset primary dystonia.
A Structurally Distinct Human Mycoplasma Protein that Generically Blocks Antigen-Antibody Union
Grover, Rajesh K., Nieusma, Travis, Jones, Teresa M., Boero, Isabel, MacLeod, Amanda S. , Mark, A, Niessen, Sherry, Kim, Helen J. , Kong, Leopold , Assad-Garcia, Nacyra , Kwon, Keehwan, Chesi, Marta , Smider, Vaughn V. , Salomon, Daniel R., Jelinek, Diane F., Kyle, Robert A. , Pyles, Richard B. , Glass, John I. , Wilson, Ian A. , Lerner, Richard A. , Zhu, Xueyong , Ward, Andrew B.

Mayo Clinic

Science | February 6, 2014 | Volume: 343 | Issue: 6171 | Pages: 656-661

10.1126/science.1246135 | PMID 24503852 Get It

Easy M Our immune systems can produce a vastly diverse repertoire of antibody molecules that each recognize and bind to a specific foreign antigen via a hypervariable region. However, there are a few bacterial antigens—such as Protein A, Protein G, and Protein L—that instead bind to the antibody's conserved regions and can bind to a large number of different antibodies. These high-affinity broad-spectrum antibody-binding properties have been widely exploited both in the laboratory and in industry for purifying, immobilizing, and detecting antibodies. Grover et al. (p. 656 ) have now identified Protein M found on the surface of human mycoplasma, which displays even broader antibody-binding specificity. The crystal structure of Protein M revealed how Protein-M binding blocks the antibody's antigen binding site. This mechanism may be exploited by mycoplasma to escape the humoral immune response.
Reduced GM1 ganglioside in CFTR-deficient human airway cells results in decreased β1-integrin signaling and delayed wound repair
Itokazu, Yutaka , Pagano, Richard E., Schroeder, Andreas S., O’Grady, Scott M. , Marks, David L. , Limper, Andrew H.

Mayo Clinic

American Journal of Physiology-Cell Physiology | February 6, 2014 | Volume: 306 | Issue: 9 | Pages: C819-C830

10.1152/ajpcell.00168.2013 | PMID 24500283 Get It

Loss of cystic fibrosis transmembrane conductance regulator (CFTR) function reduces chloride secretion and increases sodium uptake, but it is not clear why CFTR mutation also results in progressive lung inflammation and infection. We previously demonstrated that CFTR-silenced airway cells migrate more slowly during wound repair than CFTR-expressing controls. In addition, CFTR-deficient cells and mouse models have been reported to have altered sphingolipid levels. Here, we investigated the hypothesis that reduced migration in CFTR-deficient airway epithelial cells results from altered sphingolipid composition. We used cell lines derived from a human airway epithelial cell line (Calu-3) stably transfected with CFTR short hairpin RNA (CFTR-silenced) or nontargeting short hairpin RNA (controls). Cell migration was measured by electric cell substrate impedance sensing (ECIS). Lipid analyses, addition of exogenous glycosphingolipids, and immunoblotting were performed. We found that levels of the glycosphingolipid, GM1 ganglioside, were ∼60% lower in CFTR-silenced cells than in controls. CFTR-silenced cells exhibited reduced levels of activated β1-integrin, phosphorylated tyrosine 576 of focal adhesion kinase (pFAK), and phosphorylation of Crk-associated substrate (pCAS). Addition of GM1 (but not GM3) ganglioside to CFTR-silenced cells restored activated β1-integrin, pFAK, and pCAS to near control levels and partially restored (∼40%) cell migration. Our results suggest that decreased GM1 in CFTR-silenced cells depresses β1-integrin signaling, which contributes to the delayed wound repair observed in these cells. These findings have implications for the pathology of cystic fibrosis, where altered sphingolipid levels in airway epithelial cells could result in a diminished capacity for wound repair after injury.
GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features
Feldman, Andrew L. , Wada, David A., Lu, Ye , Polk, Avery , Briski, Robert , Ristow, Kay M., Ziesmer, Steven C., Wellik, Linda, Lanigan, Thomas M. , Pittelkow, Mark R. , Bailey, Nathanael G. , Hristov, Alexandra C. , Lim, Megan S. , Ansell, Stephen M. , Wang, Tianjiao , Habermann, Thomas M. , Thomas, Dafydd G. , Witzig, Thomas E. , Wilcox, Ryan A. , Feldman, Andrew L , Lim, Megan S

Mayo Clinic

Blood | February 5, 2014 | Volume: 123 | Issue: 19 | Pages: 3007-3015

10.1182/blood-2013-12-544809 | PMID 24497534 Get It

Key Points Alternatively polarized macrophages are abundant constituents of the tumor microenvironment in T-cell lymphoproliferative disorders. GATA-3 expression identifies a subset of PTCL, NOS with a distinct cytokine profile and inferior survival.
Patient-Reported Quality of Supportive Care Among Patients With Colorectal Cancer in the Veterans Affairs Health Care System
Ryn, Michelle van , Arora, Neeraj, Jackson, George L., Zafar, S. Yousuf , Zullig, Leah L. , Provenzale, Dawn, Yeazel, Mark W. , Jindal, Rahul M. , Clauser, Steven B., van Ryn, Michelle, Phelan, Sean M. , Haggstrom, David Andrew , Griffin, Joan M. , van Ryn, Michelle

Mayo Clinic

Journal of Clinical Oncology | February 4, 2014 | Volume: 32 | Issue: 8 | Pages: 809-815

10.1200/jco.2013.49.4302 | PMID 24493712 Get It

Purpose High-quality supportive care is an essential component of comprehensive cancer care. We implemented a patient-centered quality of cancer care survey to examine and identify predictors of quality of supportive care for bowel problems, pain, fatigue, depression, and other symptoms among 1,109 patients with colorectal cancer. Patients and Methods Patients with new diagnosis of colorectal cancer at any Veterans Health Administration medical center nationwide in 2008 were ascertained through the Veterans Affairs Central Cancer Registry and sent questionnaires assessing a variety of aspects of patient-centered cancer care. We received questionnaires from 63% of eligible patients (N = 1,109). Descriptive analyses characterizing patient experiences with supportive care and binary logistic regression models were used to examine predictors of receipt of help wanted for each of the five symptom categories. Results There were significant gaps in patient-centered quality of supportive care, beginning with symptom assessment. In multivariable modeling, the impact of clinical factors and patient race on odds of receiving wanted help varied by symptom. Coordination of care quality predicted receipt of wanted help for all symptoms, independent of patient demographic or clinical characteristics. Conclusion This study revealed substantial gaps in patient-centered quality of care, difficult to characterize through quality measurement relying on medical record review alone. It established the feasibility of collecting patient-reported quality measures. Improving quality measurement of supportive care and implementing patient-reported outcomes in quality-measurement systems are high priorities for improving the processes and outcomes of care for patients with cancer.
Magnetic Resonance in Medicine at 30
Glover, Gary H. , Jones, Derek K. , Frahm, Jens , Henkelman, R. Mark , Hennig, Jürgen , Riederer, Stephen J. , Wehrli, Félix W. , Bernstein, Matt A. , Maudsley, Andrew A , Bernstein, Matt A

Mayo Clinic

Magnetic Resonance in Medicine | January 29, 2014 | Volume: 71 | Issue: 3 | Pages: 901-902

10.1002/mrm.25160 | PMID 24478240 Get It

Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome
Charbonneau, Bridget, Moysich, Kirsten B., Kalli, Kimberly R., Oberg, Ann L. , Vierkant, Robert A. , Fogarty, Zachary C. , Block, Matthew S. , Goergen, Krista M., Cunningham, Julie M. , Rider, David N., Hartmann, Lynn C. , Lawrenson, Kate , Wang, Chen , Song, Honglin , DeFazio, Anna , Johnatty, Sharon E., Phelan, Catherine M., Sellers, Thomas A. , Ramirez, Starr M., Vitonis, Allison F., Terry, Kathryn L. , Pike, Malcolm C. , Wu, Anna H. , Ramus, Susan J. , Diergaarde, Brenda , Shen, Howard C., Jensen, Allan , Menkiszak, Janusz , Lubiński, Jan , Rothstein, Joseph H. , McGuire, Valerie , Sieh, Weiva , Lester, Jenny, Walsh, Christine , Vergote, Ignace , Lambrechts, Sandrina, Despierre, Evelyn, García‐Closas, Montserrat , Brinton, Louise A. , Śpiewankiewicz, Beata, Rzepecka, Iwona K. , Dansonka‐Mieszkowska, Agnieszka , Paddock, Lisa E. , Orlow, Irene , Lundvall, Lene, Olson, Sara H. , Høgdall, Claus , Schwaab, Ira, Harter, Philipp , Flanagan, James M. , Brown, Robert , Ekici, Arif B. , Beckmann, Matthias W. , Hein, Alexander , Eccles, Diana , Lurie, Galina, Hays, Laura E., Bean, Yukie T., Goodman, Marc T. , Campbell, Ian , Fasching, Peter A. , Konecny, Gottfried E. , Kaye, Stanley B., Heitz, Florian , Høgdall, Estrid , Chang‐Claude, Jenny , Kupryjańczyk, Jolanta , Wentzensen, Nicolas , Lambrechts, Diether , Whittemore, Alice S. , Culver, Hoda Anton, Levine, Douglas A. , Kjær, Susanne K. , Menon, Usha , Schildkraut, Joellen M. , Pearce, Celeste Leigh, Rossing, Mary Anne, Chenevix‐Trench, Georgia , group, for the AOCS, ACS, Gayther, Simon A. , Ness, Roberta B., Odunsi, Kunle , Sucheston, Lara E., Knutson, Keith L. , Goode, Ellen L. , Lambrechts, Diether , Maurer, Matthew J. , Fridley, Brooke L. , Preston, Claudia C. , Tyrer, Jonathan P. , Doherty, Jennifer A. , Berg, David Van Den , Berchuck, Andrew , Gentry‐Maharaj, Aleksandra , Cybulski, Cezary , Ziogas, Argyrios , Yang, Hannah , Seibold, Petra , Rudolph, Anja , Bois, Andreas du , Paul, James , Pejovic, Tanja B. , Bandera, Elisa V. , Karlan, Beth Y. , Gronwald, Jacek , Cramer, Daniel W. , group, for the AOCS, ACS, Pharoah, Paul D.P. , Knutson, Keith L. , Fazio, Anna de , Lambrechts, Diether , Kjaer, Susanne K , Ramus, Susan J , Hein, Alexander , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Lawrenson, Kate , Moysich, Kirsten , Orlow, Irene , Wang, Chen , Campbell, Ian G , Menkiszak, Janusz , Brown, Robert , Fogarty, Zachary C , Flanagan, James M , Heitz, Florian , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , García-Closas, Montserrat , Ekici, Arif B , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Diergaarde, Brenda , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Cancer Immunology Research | January 27, 2014 | Volume: 2 | Issue: 4 | Pages: 332-340

10.1158/2326-6066.cir-13-0136 | PMID 24764580 Get It

Abstract The presence of regulatory T cells (Treg) in solid tumors is known to play a role in patient survival in ovarian cancer and other malignancies. We assessed inherited genetic variations via 749 tag single-nucleotide polymorphisms (SNP) in 25 Treg-associated genes (CD28, CTLA4, FOXP3, IDO1, IL10, IL10RA, IL15, 1L17RA, IL23A, IL23R, IL2RA, IL6, IL6R, IL8, LGALS1, LGALS9, MAP3K8, STAT5A, STAT5B, TGFB1, TGFB2, TGFB3, TGFBR1, TGRBR2, and TGFBR3) in relation to ovarian cancer survival. We analyzed genotype and overall survival in 10,084 women with invasive epithelial ovarian cancer, including 5,248 high-grade serous, 1,452 endometrioid, 795 clear cell, and 661 mucinous carcinoma cases of European descent across 28 studies from the Ovarian Cancer Association Consortium (OCAC). The strongest associations were found for endometrioid carcinoma and IL2RA SNPs rs11256497 [HR, 1.42; 95% confidence interval (CI), 1.22–1.64; P = 5.7 × 10−6], rs791587 (HR, 1.36; 95% CI, 1.17–1.57; P = 6.2 × 10−5), rs2476491 (HR, = 1.40; 95% CI, 1.19–1.64; P = 5.6 × 10−5), and rs10795763 (HR, 1.35; 95% CI, 1.17–1.57; P = 7.9 × 10−5), and for clear cell carcinoma and CTLA4 SNP rs231775 (HR, 0.67; 95% CI, 0.54–0.82; P = 9.3 × 10−5) after adjustment for age, study site, population stratification, stage, grade, and oral contraceptive use. The rs231775 allele associated with improved survival in our study also results in an amino acid change in CTLA4 and previously has been reported to be associated with autoimmune conditions. Thus, we found evidence that SNPs in genes related to Tregs seem to play a role in ovarian cancer survival, particularly in patients with clear cell and endometrioid epithelial ovarian cancer. Cancer Immunol Res; 2(4); 332–40. ©2014 AACR.
A multicentre study of primary breast diffuse large B‐cell lymphoma in the rituximab era
Hosein, Peter J. , Maragulia, Jocelyn, Salzberg, Matthew, Press, Oliver W. , Bast, Martin, Advani, Ranjana H. , Tibshirani, Robert , Evens, Andrew M. , Islam, Nahida , Leonard, John P. , Martin, Peter , Lossos, Izidore S. , Habermann, Thomas M. , Vose, Julie M. , Zelenetz, Andrew D. , Press, Oliver , Advani, Ranjana H , Evens, Andrew M

Mayo Clinic

British Journal of Haematology | January 27, 2014 | Volume: 165 | Issue: 3 | Pages: 358-363

10.1111/bjh.12753 | PMID 24467658 Get It

SummaryPrimary breast diffuse large B‐cell lymphoma (DLBCL) is a rare subtype of non‐Hodgkin lymphoma (NHL) with limited data on pathology and outcome. A multicentre retrospective study was undertaken to determine prognostic factors and the incidence of central nervous system (CNS) relapses. Data was retrospectively collected on patients from 8 US academic centres. Only patients with stage I/II disease (involvement of breast and localized lymph nodes) were included. Histologies apart from primary DLBCL were excluded. Between 1992 and 2012, 76 patients met the eligibility criteria. Most patients (86%) received chemotherapy, and 69% received immunochemotherapy with rituximab; 65% received radiation therapy and 9% received prophylactic CNS chemotherapy. After a median follow‐up of 4·5 years (range 0·6–20·6 years), the Kaplan–Meier estimated median progression‐free survival was 10·4 years (95% confidence interval [CI] 5·8–14·9 years), and the median overall survival was 14·6 years (95% CI 10·2–19 years). Twelve patients (16%) had CNS relapse. A low stage‐modified International Prognostic Index (IPI) was associated with longer overall survival. Rituximab use was not associated with a survival advantage. Primary breast DLBCL has a high rate of CNS relapse. The stage‐modified IPI score is associated with survival.
Fractional Flow Reserve With Dobutamine Challenge and Coronary Microvascular Endothelial Dysfunction in Symptomatic Myocardial Bridging
Yoshino, Satoshi , Cassar, Andrew, Matsuo, Yoshiki , Herrmann, Joerg , Gulati, Rajiv , Prasad, Abhiram , Lennon, Ryan J. , Lerman, Lilach O. , Lerman, Amir , Prasad, Abhiram

Mayo Clinic

Circulation Journal | January 24, 2014 | Volume: 78 | Issue: 3 | Pages: 685-692

10.1253/circj.cj-13-0846 | PMID 24463708 Get It

Hemicraniectomy and Durotomy Upon Deterioration From Infarction-Related Swelling Trial
Frank, Jeffrey I., Schumm, L. Philip , Chyatte, Douglas, Rosengart, Axel J., Kordeck, Christi , Thisted, Ronald A., Trialists, HeADDFIRST, Bernardini, Gary L., Andrefsky, John, Krieger, Derk , Elkind, Mitchell S.V. , Coplin, William M., Graffagnino, Carmelo , Biller, José , Cruz‐Flores, Salvador , Brock, David G., Verro, Piero, Woo, Daniel , Suárez, José I. , LaMonte, Marian P. , Wroblewski, Kristen , Trialists, HeADDFIRST, Wang, David , Demchuk, Andrew M. , Pettigrew, Luther Creed

Mayo Clinic

Stroke | January 15, 2014 | Volume: 45 | Issue: 3 | Pages: 781-787

10.1161/strokeaha.113.003200 | PMID 24425122 Get It

Background and Purpose— Hemicraniectomy and Durotomy Upon Deterioration From Infarction-Related Swelling Trial (HeADDFIRST) was a randomized pilot study to obtain information necessary to design a Phase III trial to evaluate the benefit of surgical decompression for brain swelling from large supratentorial cerebral hemispheric infarction. Methods— All patients with stroke were screened for eligibility (age 18–75 years, National Institutes of Health Stroke Scale ≥18 with Item 1a<2 [responsive to minor stimulation], and CT demonstrating unilateral, complete middle cerebral artery territory infarction by specific imaging criteria). All enrolled patients were treated using a standardized medical treatment protocol. Those with both ≥4 mm of pineal shift and deterioration in level of arousal or ≥7.5 mm of anteroseptal shift within 96 hours of stroke onset were randomized to continued medical treatment only or medical treatment plus surgery. Death at 21 days was the primary outcome measure. Results— Among 4909 screened patients, only 66 (1.3%) patients were eligible for HeADDFIRST. Forty patients were enrolled, and 26 patients developed the requisite brain swelling for randomization. All who failed to meet randomization criteria were alive at 21 days. Mortality at 21 and 180 days was 40% (4/10) in the medical treatment only and 21% (3/14) and 36% (5/14) in the medical treatment plus surgery arms, respectively. Conclusions— HeADDFIRST randomization criteria effectively distinguished low from high risk of death from large supratentorial cerebral hemispheric infarction. Lower mortality in the medical treatment only group than in other published trials suggests a possible benefit to standardizing medical management. These results can inform the interpretation of recently completed European trials concerning patient selection and medical management. Clinical Trial Registration— This trial was not registered because enrollment began before July 1, 2005.